Invest New Drugs. 2020 Feb 04;:
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Haematologica. 2020 Jan 02;:
Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Expert Opin Investig Drugs. 2019 Oct;28(10):835-849
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Blood Adv. 2019 Aug 13;3(15):2307-2311
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Lancet Haematol. 2019 May 03;:
A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.
Support Care Cancer. 2018 Oct 19;:
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
Blood Adv. 2018 Oct 23;2(20):2658-2671
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.
Leuk Res. 2018 Sep 19;74:21-41
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.
Br J Haematol. 2018 Sep 11;:
Leuk Res. 2018 Feb 20;68:22-28